Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. [electronic resource]
Producer: 20150331Description: 169-76 p. digitalISSN:- 1474-5488
- Adenine -- analogs & derivatives
- Adult
- Aged
- Aged, 80 and over
- Drug Resistance, Neoplasm -- genetics
- Female
- Follow-Up Studies
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell -- drug therapy
- Male
- Middle Aged
- Mutation -- genetics
- Neoplasm Recurrence, Local -- drug therapy
- Neoplasm Staging
- Piperidines
- Prognosis
- Pyrazoles -- therapeutic use
- Pyrimidines -- therapeutic use
- Single-Blind Method
- Survival Rate
- Tumor Suppressor Protein p53 -- genetics
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.